Aytu Biopharma, Inc. (AYTU) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Eiger BioPharmaceuticals, Inc.

Aytu Biopharma, Inc.

Biofrontera, Inc.

Scorpius Holdings, Inc.

RenovoRx, Inc.

Mangoceuticals, Inc.

Moleculin Biotech, Inc.

Eterna Therapeutics, Inc.

VYNE Therapeutics, Inc.

Pasithea Therapeutics Corp.

RVL Pharmaceuticals Plc

Why is Aytu Biopharma, Inc. ?

Poor Management Efficiency with a low ROCE of 0.88%

The company has been able to generate a Return on Capital Employed (avg) of 0.88% signifying low profitability per unit of total capital (equity and debt)

Negative results in Mar 25

INTEREST(9M) At USD 2.97 MM has Grown at inf%
NET SALES(HY) At USD 34.67 MM has Grown at -15.28%
CASH AND EQV(HY) Lowest at USD 38.57 MM

Risky - Market Cap of less than 100 cr

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 34.71%, its profits have risen by 152.7% ; the PEG ratio of the company is 0

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Aytu Biopharma, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Aytu Biopharma, Inc.

41.29%

-0.27

118.20%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

36.72%

EBIT Growth (5y)

15.10%

EBIT to Interest (avg)

-19.56

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.10

Sales to Capital Employed (avg)

1.49

Tax Ratio

39.13%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

31.84%

ROCE (avg)

0.88%

ROE (avg)

3.26%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.35

EV to EBIT

15.69

EV to EBITDA

2.23

EV to Capital Employed

0.41

EV to Sales

0.23

PEG Ratio

0.01

Dividend Yield

ROCE (Latest)

0.96%

ROE (Latest)

16.29%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Mildly Bullish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

25What is working for the Company

ROCE(HY)

Highest at 3.29%

NET PROFIT(Q)

Highest at USD 3.94 MM

NET SALES(Q)

Highest at USD 18.45 MM

OPERATING PROFIT(Q)

Highest at USD 3.74 MM

OPERATING PROFIT MARGIN(Q)

Highest at 20.26 %

PRE-TAX PROFIT(Q)

Highest at USD 3.82 MM

EPS(Q)

Highest at USD 0.21

-11What is not working for the Company

INTEREST(9M)

At USD 2.97 MM has Grown at inf%

NET SALES(HY)

At USD 34.67 MM has Grown at -15.28%

CASH AND EQV(HY)

Lowest at USD 38.57 MM

INVENTORY TURNOVER RATIO(HY)

Lowest at 2.13 times

DEBTORS TURNOVER RATIO(HY)

Lowest at 2.11 times

Here's what is working for Aytu Biopharma, Inc.

Pre-Tax Profit

At USD 3.82 MM has Grown at 259.22%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (USD MM)

Net Profit

At USD 3.94 MM has Grown at 249.07%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (USD MM)

Net Profit

Highest at USD 3.94 MM and Grown

In each period in the last five periods

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (USD MM)

Net Sales

Highest at USD 18.45 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (USD MM)

Operating Profit

Highest at USD 3.74 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (USD MM)

Operating Profit Margin

Highest at 20.26 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

Highest at USD 3.82 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

EPS

Highest at USD 0.21

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Here's what is not working for Aytu Biopharma, Inc.

Interest

At USD 2.97 MM has Grown at inf%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Cash and Eqv

Lowest at USD 38.57 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Inventory Turnover Ratio

Lowest at 2.13 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Debtors Turnover Ratio

Lowest at 2.11 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio